Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

BACKGROUND: Ridaforolimus is a mammalian target of rapamycin inhibitor that has activity in solid tumors. Paclitaxel and carboplatin have broad antineoplastic activity in many cancers. This phase I trial was conducted to determine the safety profile, maximal tolerated dose, and recommended phase II...

Descripción completa

Detalles Bibliográficos
Autores principales: Chon, Hye Sook, Kang, Sokbom, Lee, Jae K., Apte, Sachin M., Shahzad, Mian M., Williams-Elson, Irene, Wenham, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465458/
https://www.ncbi.nlm.nih.gov/pubmed/28595616
http://dx.doi.org/10.1186/s12885-017-3394-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465458/
https://www.ncbi.nlm.nih.gov/pubmed/28595616
http://dx.doi.org/10.1186/s12885-017-3394-2

Ejemplares similares